United States securities and exchange commission logo

                               December 16, 2022

       Geoffrey S. Dow, Ph.D.
       President and Chief Executive Officer
       60 Degrees Pharmaceuticals, Inc.
       1025 Connecticut Avenue NW Suite 1000
       Washington, D.C. 20036

                                                        Re: 60 Degrees
Pharmaceuticals, Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted December
5, 2022
                                                            CIK No. 0001946563

       Dear Geoffrey S. Dow:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional

       Amendment No. 1 to Draft Registration Statement on Form S-1, submitted
December 5, 2022

       Prospectus Summary, page 4

   1.                                                   We note your response
to prior comment 2 and your inclusion of the pipeline table on
                                                        pages 5 and 65. Please
revise your pipeline table to remove the "Earliest Possible
                                                        Marketing Date in USA"
column. Given that FDA approval of your products for the
                                                        treatment of your
stated indications is not within your control, it is inappropriate to predict
                                                        the earliest date that
such approval may be obtained for all of your products aside from
                                                        Arakoda, which has been
approved by the FDA only for the prevention of malaria. As
                                                        requested by our prior
comment, please also depict the phase or status of development for
                                                        each product candidate
including separate columns for preclinical development, Phase 1,
                                                        Phase 2 and Phase 3
trials with arrows showing where each program has progressed.
 Geoffrey S. Dow, Ph.D.
60 Degrees Pharmaceuticals, Inc.
December 16, 2022
Page 2
Strategy, page 8

2.       We note your disclosure that in 2023, you plan to execute a
randomized, placebo-
         controlled double blind clinical study to prove that Arakoda
accelerates time to sustained
         clinical recovery in patients with mild-moderate disease with no risk
factors. Since your
         previous Phase II trial was terminated early, please clarify whether
the new trial will be
         Phase II or Phase III.
Key Relationships & Licenses, page 10

3.       Please disclose the maximum amount in milestone payments that could be
due under the
         Exclusive License Agreement with the U.S. Army Medical Materiel
Common stock to be outstanding after the offering, page 15

4.       We note your response to prior comment 11. Please expand footnote 3 to
address the
         common stock that could be issuable upon conversion of the preferred
stock that will be
         issued for accrued interest on the Knight Loan. Please also revise
this section to indicate
         what disclosure this footnote is intended to modify.
Business, page 64

5.       We note your response to prior comment 18 and your inclusion of the
section entitled
         "Key Relationships & Licenses." We reissue our prior comment in part.
In an appropriate
         location, disclose how your licensing arrangement with the United
States Army, which
         you disclose excludes P. vivax malaria, would impact any targeted
marketing efforts of
         Arakoda for its currently approved use.
Arakoda, page 66

6.     We note your response to prior comment 19 and your revised disclosure on
page 66. We
       reissue our comment in part. If any of the p-values from Phase II of the
       investigation were not statistically significant, please clarify that
here and include
       balancing disclosure in your prospectus summary. Please also clarify
here and in your
       prospectus summary whether the trial was designed to show if the
observed results could
       be due to the administration of Arakoda on a standalone basis, or prior
COVID infection,
FirstName LastNameGeoffrey S. Dow, Ph.D.
       prior vaccination, or both, or whether the results could be due to
chance. We also note the
Comapany    Name60
       p-value       Degrees
               in Figure B onPharmaceuticals,
                               page 8 is 0.1209.Inc.
                                                   If the results shown could
be due to chance,
       please revise to
December 16, 2022 Page 2make  that clear.
FirstName LastName
 Geoffrey S. Dow, Ph.D.
60 DegreesLastNameGeoffrey    S. Dow, Ph.D.
           Pharmaceuticals, Inc.
December   Name60
              2022 Degrees Pharmaceuticals, Inc.
Page 3    16, 2022 Page 3
FirstName LastName
        You may contact Franklin Wyman at 202-551-3660 or Angela Connell at
if you have questions regarding comments on the financial statements and
matters. Please contact Joshua Gorsky at 202-551-7836 or Tim Buchmiller at
3635 with any other questions.


                                                       Division of Corporation
                                                       Office of Life Sciences
cc:      Ross D. Carmel, Esq.